Pressmeddelanden

LIPIGON PHARMACEUTICALS JOINS ASTRAZENECA'S BIOVENTURHUB

Starting December 2016 Lipigon joins the AZ BioVentureHub located at AstraZeneca's site in Mölndal, Sweden. The contract stretches over 1 year giving Lipigon an office and full access to the whole facility, including infrastructure and capabilities.

The BioVentureHub is an initiative from AstraZeneca to support the Swedish life science ecosystem. It gives the participating companies the possibility to utilize AstraZeneca's expertise and benefit from an innovative environment.

"This is a great opportunity for Lipigon and we are pleased to join the BioVentureHub. Being part of the Hub will help us grow. We can utilize the expertise of AstraZeneca in all our projects and we will be part of an innovative environment where we also get closer to our existing collaboration partners - AstraZeneca and Antaros Medical. The flexible structure suits us perfectly. In the future, we can expand from having an office into having our own lab." said Stefan K Nilsson, CEO and co-founder at Lipigon.

The excitement is shared by AstraZeneca;

"I am particularly pleased to welcome Lipigon to the AstraZeneca BioVentureHub as it will enable us to work closely on our existing collaboration in the area of lipid disorders and stabilization of Lipoprotein Lipase (LPL), said Marcus Schindler, Vice President, Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit, AstraZeneca. "Lipigon are recognized for their expertise in the challenging area of LPL biology. Co-locating Lipigon's team next to AstraZeneca's drug discovery scientists will help accelerate our joint efforts to discover differentiated therapies while also strengthening the entire BioVentureHub ecosystem."

For further information, please contact:
Stefan K. Nilsson, CEO, Lipigon Pharmaceuticals
e-mail: stefan@lipigon.se
Tel: +46 70 578 17 68

About Lipigon

Lipigon is a spin out from Umeå University in Sweden. The company was founded by leading scientists in the field of cellular lipid transport. Lipigon is currently focusing on the discovery and development of novel treatments for dyslipidemia and metabolic diseases. For more information please visit: www.lipigon.se

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

About AZBioVentureHub

For more information please visit www.azbioventurehub.com

2020-06-30

Lipigon Pharmaceuticals AB ("Lipigon") har framgångsrikt avslutat en
nyemission av aktier som tillför bolaget närmare 16,7 miljoner kronor. Kapitalet
ska primärt användas för att ta bolagets huvudprogram mot kliniska studier.

2020-06-30

Lipigon Pharmaceuticals has successfully closed a new share issue of nearly € 1,6 million. The capital raised will primarily be used to take the most advanced programme of the company towards clinical trials.

2020-05-14

Lipigon Pharmaceuticals AB ("Lipigon"), som utvecklar läkemedel mot
sjukdomar orsakade av rubbningar i kroppens hantering av fetter, tillkännager
idag att bolaget har ingått ett avtal med HitGen Inc. ("HitGen") som är noterat
på Shanghai-börsen. Bolagen kommer tillsammans att bedriva forskning för att
identifiera och utveckla läkemedelskandidater som påverkar enzymet LPL som
ansvarar för nedbrytning av blodfetter. Målet är att utveckla behandlingar av
hjärt-sjukdom och andra fettrelaterade sjukdomar.

2020-05-14

Lipigon enters agreement with HitGen to develop drugs for cardiometabolic diseases Lipigon Pharmaceuticals AB ("Lipigon"), developer of therapeutics for lipid-related diseases, today announced that the company has entered an agreement with STAR listed (Shanghai market) company HitGen Inc. ("HitGen"). The companies will conduct joint research to identify and develop drug candidates that enhance the activity of Lipoprotein Lipase (LPL), with the aim to be used in treatment of lipid disorders and cardiovascular disease.

2020-03-23

Lipigon Pharmaceuticals ("Lipigon") tillkännagav idag att bolaget har förvärvat en RNA-läkemedelskandidat baserad på antisens-teknologin som tagits fram med Secarna Pharmceuticals ("Secarna") inom ramen för ett tidigare forskningssamarbete. Lipgion kommer att bedriva fortsatt forskning och utveckling av de förvärvade tillgångarna som inriktar sig på ANGPTL, en genfamilj som bland annat står för reglering av blodfetter. Secarna kommer att erhålla marknadsmässiga betalningar för transaktionen. Parterna har valt att inte offentliggöra närmare detaljer om ersättningen.

2020-03-23

Lipigon acquires antisense drug candidates for cardiovascular and metabolic diseases from Secarna Lipigon Pharmaceuticals ("Lipigon") announced that the company has acquired antisense drug candidates jointly generated with Secarna Pharmaceuticals ("Secarna") under a previous research collaboration. Lipigon will continue the research and development of the acquired assets targeting the ANGPTL gene family, and Secarna will receive undisclosed payments customary for such a transaction.

2019-10-10

Lipigon Pharmaceuticals ("Lipigon") tillkännager att bolaget har ingått ett avtal om samarbete och utlicensiering med CombiGene AB (publ) ("CombiGene") avseende utveckling av en avancerad genterapi för behandling av den sällsynta sjukdomen lipodystrofi. Lipigon och CombiGene kommer inom ramen för avtalet att samarbeta under projektets tidiga utvecklingsfaser.

2017-12-09

Lipigons VD Dr. Stefan K Nilsson väljs in i The European Lipoprotein Club (ELC), det äldsta och mest aktiva europeiska nätverket inom lipidfältet. ELC etablerades 1977 för att främja samarbete och utbyte av idéer inom grundforskning och klinisk forskning på lipoproteiner (blodfettskomplex).

2017-10-10

Lipigon Pharmaceuticals ("Lipigon") tillkännagav idag att bolaget har tecknat avtal avseende validering av målprotein för läkemedelsutveckling med Secarna Pharmaceuticals ("Secarna") som är specialiserat på RNA-behandlingar genom s.k. antisens-teknologi. Målet är att tillsammans utveckla ett läkemedel som är best-in-class för behandling av allvarliga former av dyslipidemi (allmänna blodfettsrubbningar) och närliggande sjukdomar.

2017-10-10

Lipigon Pharmaceuticals ("Lipigon") announced today that it has entered into a Target Validation Research Agreement with Munich-based antisense therapeutics company Secarna Pharmaceuticals ("Secarna"). The goal is to co-develop a best-in-class drug for treatment of severe forms of dyslipidemia and related lipid disorder driven diseases.

2016-12-26

Starting December 2016 Lipigon joins the AZ BioVentureHub located at AstraZeneca's site in Mölndal, Sweden. The contract stretches over 1 year giving Lipigon an office and full access to the whole facility, including infrastructure and capabilities.

2016-12-01

Lipigon is happy to announce 3 new major partners investing in the company. Umeå based Fort Knox Förvaltning AB (Owner of Balticgruppen) and Partnerinvest Övre Norrland AB together with Antaros Medical AB in Gothenburg have entered as new shareholders. The investments allow for Lipigon to expand within present programs and to evaluate novel targets.

<<
1
...
10
11
12
13
>>

Nyheter

27 januari, 2023, Pressmeddelande

Lipigon tar sikte på fas II

Under den senaste tiden har Lipigon kommit med flera positiva nyheter om bolagets blodfettssänkande ...

23 januari, 2023, Pressmeddelande

Lipigons vd Stefan K. Nilsson ökar sitt innehav i bolaget

Lipigon Pharmaceuticals AB ("Lipigon") meddelar i dag att vd Stefan K. Nilsson har köpt aktier i Lip...

19 januari, 2023, Pressmeddelande

Lipigon rapporterar ytterligare positiva data från fas I-studie med Lipisense

Lipigon Pharmaceuticals AB ("Lipigon") tillkännagav i dag positiva säkerhetsresultat från fas I-stud...